Navigation Links
Novexel's NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
Date:11/12/2008

tion of antibiotic therapy for each patient should be 7 to 14 days. The results of this study are expected in late 2009.

In completed Phase I studies in healthy subjects NXL104/ceftazidime was generally well tolerated and the pharmacokinetics of the two components were well matched. Additional studies in special populations are ongoing.

Iain Buchanan, Novexel's CEO, said, "We continue to believe that this novel combination, which is based around our novel beta-lactamase inhibitor, NXL104, has the potential to play an important role in confronting the increasing problem of hospital infections caused by resistant Gram negative bacteria. The start of our first Phase II study with NXL104 in combination with ceftazidime is an important milestone for the company."

Under an independent development program, Forest Laboratories (NYSE : FRX) will combine NXL104 in a treatment regimen with Forest's ceftaroline, a novel, bactericidal injectable broad spectrum cephalosporin being developed as a therapeutic agent for the treatment of gram-positive pathogens including methicillin resistant staphylococcus aureus (MRSA), and multi-drug resistant streptococcus pneumoniae (MDRSP), as well as common gram-negative organisms. Ceftaroline is being studied as a monotherapy in Phase III clinical trials by Forest. In January 2008, Novexel granted Forest a license to develop, manufacture and commercialise NXL104, only in combination with ceftaroline, in North America.

Novexel retains worldwide rights on the NXL104/ceftazidime combination.

About NXL104

NXL104 is a novel injectable non beta lactam, beta-lactamase inhibitor, which is being developed to address the increasing problem of microbial resistance to beta lactam antibiotics (penicillins, cephalosporins, carbopenems) mediated by beta-lactamase enzymes. NXL104 is a significant advance, as it is able to inhibit a broader range of beta-lactamases than currently marketed beta-lactam inhibitors. Its s
'/>"/>

SOURCE Novexel
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
2. Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults
3. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
4. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
5. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
6. Particle Sciences Expands Its Combination Product Capabilities
7. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
8. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
10. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
11. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 Edwards Lifesciences Corporation (NYSE: EW ), ... hemodynamic monitoring, today announced that Robert A. Ingram ... "Bob is an ardent champion for innovation in the lifesciences ... him on Edwards, board as we pursue our focused innovation ... CEO.  "Bob has provided a valuable perspective to our board, ...
(Date:7/30/2015)... Inc. (NYSE: RMD ) today announced results for ... quarter was $453.1 million, a 9 percent increase compared ... percent increase on a constant currency basis).  Net income ... 30, 2014.  Diluted earnings per share for the quarter ... 2014.  The results for the quarter ...
(Date:7/30/2015)... , July 30, 2015  Unichem Pharmaceuticals ( ... one lot of Hydrochlorothiazide tablets 25 mg 1000-count bottle ... as a precautionary measure due to the identification of ... product. The risk associated with mistakenly ... is the increased probability of experiencing Clopidogrel,s side effects ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
... new white paper urges medical device and combination product ... as a means of preventing the failure of ... medical products are based on years of data that ... occur due to inadequate package validation programs," said Steven ...
... 16, 2010 Reportlinker.com announces that a new ... Global Analgesics Industry ... the worldwide markets for Analgesics in US$ Million ... Ibuprofen, and Others (includes combination drugs)), and External ...
Cached Medicine Technology:New White Paper: Having a Solid Package Validation Program Can Prevent Failure of Combination Products 2New White Paper: Having a Solid Package Validation Program Can Prevent Failure of Combination Products 3Reportlinker Adds Global Analgesics Industry 2Reportlinker Adds Global Analgesics Industry 3Reportlinker Adds Global Analgesics Industry 4Reportlinker Adds Global Analgesics Industry 5Reportlinker Adds Global Analgesics Industry 6Reportlinker Adds Global Analgesics Industry 7Reportlinker Adds Global Analgesics Industry 8Reportlinker Adds Global Analgesics Industry 9Reportlinker Adds Global Analgesics Industry 10Reportlinker Adds Global Analgesics Industry 11Reportlinker Adds Global Analgesics Industry 12Reportlinker Adds Global Analgesics Industry 13Reportlinker Adds Global Analgesics Industry 14Reportlinker Adds Global Analgesics Industry 15Reportlinker Adds Global Analgesics Industry 16Reportlinker Adds Global Analgesics Industry 17Reportlinker Adds Global Analgesics Industry 18Reportlinker Adds Global Analgesics Industry 19Reportlinker Adds Global Analgesics Industry 20Reportlinker Adds Global Analgesics Industry 21
(Date:8/1/2015)... ... August 01, 2015 , ... Brig and Lita Hart, icons of the network ... their Healthy Home mission with the HOPE Movement of EvolvHealth. In what has been ... companies have agreed to join their missions of purpose together to change the course ...
(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... Lume Wellness ... that is free to download on the Apple AppStore. , The app is ... even mood, thus acting as a tool to view personal health and use this ...
(Date:8/1/2015)... ... 2015 , ... On March 19, 2015 Phil Valentine – the Executive Director of Connecticut Community ... by stepping off Springer Mountain and heading north. Since that day, Phil has hiked ... and was greeted by friends and family. He visited CCAR and left an inspirational ...
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot ... their new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) ... To commemorate introduction of this new type of sod, Super-Sod is giving away red ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable source for ... Chicago at Grant Park. The festival will end on Sunday, August 2nd. ... for the annual Lollapalooza. This unique and unbelievably popular festival attracts the best ...
Breaking Medicine News(10 mins):Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2
... 20 Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: ... its epigenetic technology successfully inhibits tumor growth.The results ... at the 100th Annual American Association for Cancer ... in ,switching on, important anti-cancer genes - a ...
... April 20 A new alliance between the ... leading manufacturer of unattended massage beds is focused ... a new and affordable service to customers.(Photo: ... Enterprises manufactures the HydroMassage, a massage system that ...
... the University of Southern California have identified a new ... surrounding blood vessels without the negative side effects typically ... 2.5-dimethyl-celecoxib (DMC) appears to have a strong anti-tumor effect ... supply necessary for tumor growth, according to data presented ...
... Fluorescent Channels to Enable Greater Data Ranges and Multiplexing ... Series Launched to Enable Imaging, Co-Registration and Data Fusion ... April 20 VisEn Medical Inc., a ... research through medicine, announced that users of its FMT ...
... added everolimus (Afinitor(R), Novartis) to the NCCN Guidelines for ... renal cell carcinoma whose disease has progressed after treatment ... of the March 30, 2009 FDA approval of everolimus ... that the therapy significantly extended progression-free survival in a ...
... Schwabe North America , has announced the ... Way sales teams. The integration marks an exciting ... Inc. by German-based Dr. Willmar Schwabe Pharmaceuticals, a leading ... years.The combined Specialty Retail Field Sales Team will service ...
Cached Medicine News:Health News:Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth 2Health News:Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth 3Health News:Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth 4Health News:ETS Tan Now Exclusive Distributor of HydroMassage in U.S. 2Health News:USC researchers develop new drug to target tumor cells and blood vessels 2Health News:VisEn Medical Launches Expanded FMT 2500(TM) Imaging Platforms at AACR Meeting 2Health News:VisEn Medical Launches Expanded FMT 2500(TM) Imaging Platforms at AACR Meeting 3Health News:NCCN Updates Kidney Cancer Guidelines to Incorporate FDA Approval of Everolimus 2Health News:NCCN Updates Kidney Cancer Guidelines to Incorporate FDA Approval of Everolimus 3Health News:Schwabe North America Integrates Enzymatic Therapy and Nature's Way Sales Teams 2
For regulating sample flow rate when using the QIAvac 24 Plus;...
Holder for QIAGEN 96-well plates, for use with QIAvac 96;...
For connecting the QIAvac 24 Plus and Vacuum Pump;...
For monitoring vacuum pressure, suitable for use with all QIAvac manifolds;...
Medicine Products: